Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 3/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | HRH1 | P35367 | 2/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.32 |
| ▸ | HTR1D | P28221 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9244730 | 1.00 | CHRNB2 (0.42) | CHRNB2CHRNB4CHRNA3CHRNA4HTR1A | |
| SCHEMBL28296415 | 0.79 | HTR2A (0.40) | CHRNB2CHRNB4CHRNA3CHRNA4HTR2A | |
| SCHEMBL3185620 | 0.77 | HTR1A (0.49) | CHRNB2CHRNB4CHRNA3CHRNA4HTR1A | |
| SCHEMBL23072425 | 0.77 | CHRNB2 (0.45) | CHRNB2CHRNB4CHRNA3CHRNA4HTR1A | |
| SCHEMBL1134192 | 0.76 | CA2 (0.44) | CHRNB2CHRNB4CHRNA3CHRNA4HTR1A | |
| SCHEMBL27927044 | 0.76 | HTR1A (0.43) | CHRNB2CHRNB4CHRNA3CHRNA4HTR1A | |
| SCHEMBL20328822 | 0.76 | HTR1A (0.44) | CHRNB2CHRNB4CHRNA3CHRNA4HTR1A | |
| SCHEMBL22660797 | 0.76 | HTR1A (0.48) | CHRNB2CHRNB4CHRNA3CHRNA4HTR1A | |
| SCHEMBL6577366 | 0.76 | HTR1A (0.44) | CHRNB2CHRNB4CHRNA3CHRNA4HTR1A | |
| SCHEMBL10318359 | 0.76 | HTR1A (0.44) | CHRNB2CHRNB4CHRNA3CHRNA4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-7188065-A | — | — | None | — | — | JP | disclosed |
| CN-118497160-A | Ketone reductase mutant and application thereof | 杭州善泰生物科技有限公司 | 2024-08-16 | — | — | CN | disclosed |
| US-8362279-B2 | Process for pure duloxetine hydrochloride | MSN LABORATORIES LIMITED (IN) | 2013-01-29 | — | — | US | disclosed |
| US-8362279-B2 | Process for pure duloxetine hydrochloride | MSN LABORATORIES LIMITED (IN) | 2013-01-29 | — | — | US | disclosed |
| US-20090012315-A1 | Process for Pure Duloxetine Hydrochloride | MSN LABORATORIES LIMITED (IN) | 2009-01-08 | — | — | US | disclosed |
| US-20090012315-A1 | Process for Pure Duloxetine Hydrochloride | MSN LABORATORIES LIMITED (IN) | 2009-01-08 | — | — | US | disclosed |
| WO-2007077580-A2 | IMPROVED PROCESS FOR PURE DULOXETINE HYDROCHLORIDE | MSN LABORATORIES LIMITED (IN) | 2007-07-12 | — | — | WO | disclosed |
| JP-H07188065-A | ASYMMETRIC SYNTHESIS OF DOLOXETINE | ELI LILLY & CO | 1995-07-25 | — | — | JP | disclosed |
| US-5023269-A | 3-aryloxy-3-substituted propanamines | ELI LILLY AND COMPANY (US) | 1991-06-11 | — | — | US | disclosed |
| EP-0273658-B1 | 3-ARYLOXY-3-SUBSTITUTED PROPANAMINES | ELI LILLY AND COMPANY (US) | 1990-10-31 | — | — | EP | disclosed |
| US-4956388-A | ANTIDEPRESSANTS, ANTIANXIETY, TREATMENT OF OBESITY, ADDICTION TO SMOKING AND ALCOHOL | ELI LILLY AND COMPANY (US) | 1990-09-11 | — | — | US | disclosed |
| EP-0273658-A1 | 3-Aryloxy-3-substituted propanamines | ELI LILLY AND COMPANY (US) | 1988-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012315-A1 | Process for Pure Duloxetine Hydrochloride | OPRK1, OPRM1, OPRD1 | CHRNB2 261/4885CHRNB4 206/4885CHRNA3 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.